Sign in Subscribe
Diseases

Chronic Obstructive Pulmonary Disease Market Forecast 2024-2034: Competitive Intelligence & Growth Drivers for Pharma Stakeholders

Strategic Insights

— 2 min read

The chronic obstructive pulmonary disease (COPD) market is expected to experience steady growth in the coming years, driven primarily by increasing diagnosed prevalent cases and the introduction of novel biologics and combination therapies by key COPD companies, including Sanofi, Regeneron Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and Amgen. The report forecasts that the COPD market size in the 7MM (United States, EU4, United Kingdom, and Japan) will grow considerably during the forecast period (2024-2034), with the US dominating the market share in 2023, representing approximately 62% of the total market share.

Key Takeaways:

  • The COPD market size in the 7MM is expected to grow from approximately USD 16 billion in 2023 to reach USD 32 billion by 2034, at a Compound Annual Growth Rate (CAGR) of 7.1%.
  • The US is expected to dominate the COPD market in 2023, representing approximately 62% of the total market share, followed by the EU4 and UK, which collectively will capture the second-largest COPD market share.
  • The COPD patient population in the 7MM is expected to increase from approximately 44 million in 2023 to reach 57 million by 2034, at a CAGR of 2.8%.
  • The most common subtype of COPD is chronic bronchitis, accounting for 43% of the total COPD cases in 2023, followed by emphysema, which accounted for 31% of the total COPD cases.
  • The COPD treatment landscape is categorized into three main segments: Monotherapies, Double Combination Therapies, and Triple Combination Therapies, with Double Combination Therapies generating the highest market revenue in 2023, reaching approximately USD 9 billion.
  • The most widely used COPD therapies in 2023 were Duaklir Pressair by AstraZeneca, DUPIXENT by Regeneron Pharmaceuticals and Sanofi, and BYDURET by AstraZeneca.
  • The COPD market is expected to witness the launch of several emerging therapies, including Itepekimab, FASENRA, and NUCALA, which are expected to have a significant impact on the market share.

Statistics:

  • COPD patient population in the 7MM: 44 million in 2023, expected to increase to 57 million by 2034, at a CAGR of 2.8%.
  • COPD market size in the 7MM: USD 16 billion in 2023, expected to grow to USD 32 billion by 2034, at a CAGR of 7.1%.
  • US COPD market share: 62% in 2023.
  • EU4 and UK COPD market share: 24% in 2023.
  • COPD market growth rate: 7.1% CAGR from 2023 to 2034.
  • Duaklir Pressair market revenue: USD 4.1 billion in 2023.
  • DUPIXENT market revenue: USD 2.5 billion in 2023.

Sources:

  • DelveInsight's "Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034"
  • M2 PressWIRE (Aug 27, 2025)
  • Regulatory documents
  • Clinical trial findings
  • Expert interviews

Read more